• Consensus Rating: Hold
  • Consensus Price Target: $4.75
  • Forecasted Upside: 172.99 %
  • Number of Analysts: 5
  • Breakdown:
  • 1 Sell Ratings
  • 4 Hold Ratings
  • 0 Buy Ratings
  • 0 Strong Buy Ratings
$1.74
+0 (0.00%)

This chart shows the closing price for VAPO by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Vapotherm Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for VAPO and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for VAPO

Analyst Price Target is $4.75
▲ +172.99% Upside Potential
This price target is based on 5 analysts offering 12 month price targets for Vapotherm in the last 3 months. The average price target is $4.75, with a high forecast of $7.00 and a low forecast of $2.00. The average price target represents a 172.99% upside from the last price of $1.74.

This chart shows the closing price for VAPO for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Hold

The current consensus among 5 contributing investment analysts is to hold stock in Vapotherm. This rating has held steady since September 2021, when it changed from a Sell consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 2 hold ratings
  • 1 sell ratings
2/24/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
5/25/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 1 sell ratings
8/23/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 1 hold ratings
  • 1 sell ratings
11/21/2021
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
2/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
5/20/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 3 hold ratings
  • 1 sell ratings
7/19/2022
  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings
8/18/2022

Latest Recommendations

  • 0 strong buy ratings
  • 0 buy ratings
  • 4 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
8/4/2022BTIG ResearchDowngradeBuy ➝ NeutralLow
8/4/2022William BlairDowngradeOutperform ➝ Market PerformLow
8/4/2022Piper SandlerLower TargetUnderweight$2.50 ➝ $2.00Low
6/24/2022BTIG ResearchLower TargetBuy$9.00 ➝ $7.00Low
5/26/2022Piper SandlerLower TargetUnderweight$5.00 ➝ $2.50Low
5/6/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$12.00 ➝ $5.00High
5/6/2022Canaccord Genuity GroupDowngradeBuy ➝ Hold$12.00 ➝ $5.00High
5/5/2022Piper SandlerLower Target$8.00 ➝ $5.00High
4/18/2022BTIG ResearchLower Target$37.00 ➝ $10.00High
4/13/2022Canaccord Genuity GroupLower Target$21.00 ➝ $12.00Medium
4/13/2022Canaccord Genuity GroupLower TargetBuy$21.00 ➝ $12.00Medium
4/7/2022Piper SandlerDowngradeOverweight ➝ Underweight$23.00 ➝ $8.00High
2/25/2022Canaccord Genuity GroupLower Target$35.00 ➝ $21.00High
1/13/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$41.00 ➝ $35.00High
1/13/2022Canaccord Genuity GroupLower TargetBuy ➝ Buy$41.00 ➝ $35.00High
9/27/2021BTIG ResearchReiterated RatingBuy$45.00Medium
2/25/2021Piper SandlerLower TargetOverweight$39.00 ➝ $36.00High
1/15/2021Piper SandlerBoost TargetOverweight$36.00 ➝ $39.00Low
12/17/2020Piper SandlerInitiated CoverageOverweight$36.00High
8/4/2020BTIG ResearchReiterated RatingBuy$53.00High
7/13/2020BTIG ResearchBoost Target$32.00 ➝ $53.00High
5/26/2020BTIG ResearchReiterated RatingBuy$32.00High
5/5/2020BTIG ResearchReiterated RatingBuy$32.00High
3/5/2020William BlairReiterated RatingOutperformMedium
3/5/2020BTIG ResearchReiterated RatingBuy$23.00High
12/10/2018William BlairReiterated RatingOutperformHigh
12/10/2018Bank of AmericaInitiated CoverageBuy ➝ Buy$26.00Medium
12/10/2018BTIG ResearchInitiated CoverageBuyHigh
12/10/2018William BlairInitiated CoverageOutperform ➝ OutperformHigh
(Data available from 8/18/2017 forward)

News Sentiment Rating

-0.18 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 1 very negative mentions
1/20/2022
  • 1 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
2/19/2022
  • 4 very positive mentions
  • 6 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
3/21/2022
  • 2 very positive mentions
  • 6 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
4/20/2022
  • 0 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
5/20/2022
  • 0 very positive mentions
  • 2 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
6/19/2022
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
7/19/2022
  • 1 very positive mentions
  • 13 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
8/18/2022

Current Sentiment

  • 1 very positive mentions
  • 13 positive mentions
  • 7 negative mentions
  • 3 very negative mentions
Vapotherm logo
Vapotherm, Inc., a medical technology company, focuses on the development and commercialization of proprietary high velocity therapy products used to treat patients of various ages suffering from respiratory distress in the United States and internationally. The company offers precision flow systems, such as Precision Flow Hi-VNI, Precision Flow Plus, Precision Flow Classic, and Precision Flow Heliox that deliver heated, humidified, and oxygenated air at a high velocity to patients through a small-bore nasal interface. It also provides companion products, including Vapotherm Transfer Unit, which allows patients to be transferred between care areas within the hospital or ambulate while on therapy; Q50 compressor, which provides compressed air necessary to run the precision flow systems; aerosol aeroneb adaptor to facilitate delivery of ultrasonic aerosolized medication; aerosol disposable patient circuit that is designed to streamline the provision of continuous and intermittent delivery of aerosol medication; and tracheostomy adaptors. In addition, Vapotherm, Inc. offers ProSoft cannula to provide gentle contact with the skin; and disposable products comprising single-use disposables and nasal interfaces, as well as Oxygen Assist Modules, which helps clinicians maintain oxygen levels within a target range. The company sells its products to hospitals. Vapotherm, Inc. was founded in 1993 and is headquartered in Exeter, New Hampshire.
Read More

Today's Range

Now: $1.74
Low: $1.69
High: $1.74

50 Day Range

MA: $2.33
Low: $1.62
High: $3.30

52 Week Range

Now: $1.74
Low: $1.62
High: $31.87

Volume

2,633 shs

Average Volume

228,396 shs

Market Capitalization

$46.46 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Vapotherm?

The following equities research analysts have issued research reports on Vapotherm in the last year: BTIG Research, Canaccord Genuity Group Inc., Piper Sandler, and William Blair.
View the latest analyst ratings for VAPO.

What is the current price target for Vapotherm?

4 Wall Street analysts have set twelve-month price targets for Vapotherm in the last year. Their average twelve-month price target is $4.75, suggesting a possible upside of 173.0%. BTIG Research has the highest price target set, predicting VAPO will reach $7.00 in the next twelve months. Piper Sandler has the lowest price target set, forecasting a price of $2.00 for Vapotherm in the next year.
View the latest price targets for VAPO.

What is the current consensus analyst rating for Vapotherm?

Vapotherm currently has 1 sell rating and 4 hold ratings from Wall Street analysts. The stock has a consensus analyst rating of "Hold." A "hold" rating indicates that analysts believe investors should keep any existing positions they have in VAPO, but not buy more shares or sell existing shares.
View the latest ratings for VAPO.

What other companies compete with Vapotherm?

How do I contact Vapotherm's investor relations team?

Vapotherm's physical mailing address is 100 DOMAIN DRIVE, EXETER NH, 03833. The company's listed phone number is (866) 410-9986 and its investor relations email address is [email protected] The official website for Vapotherm is www.vapotherm.com. Learn More about contacing Vapotherm investor relations.